Please assess the completion status of the following clinical trial:

Trial Title: Fotemustine in Treating Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed metastatic malignant melanoma, meeting the following criteria:~  * Metastatic lymph nodes or skin allowing for surgical resection~ * At least 1 metastatic lesion (lymph nodes, skin, visceral, brain)~* Measurable or evaluable disease~PATIENT CHARACTERISTICS:~* WHO performance status 0-2~* ANC \> 2 x 10\^9/L~* Platelet count \> 100 x 10\^9/L~* Transaminases ≤ 2.5 times normal~* Alkaline phosphate ≤ 2.5 times normal~* Total bilirubin normal~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No severe uncontrolled infection~* No other prior or concurrent malignancy (except basal cell or squamous cell carcinoma in situ of the cervix that was curatively treated)~PRIOR CONCURRENT THERAPY:~* No prior chemotherapy~* At least 2 weeks since prior adjuvant therapy~* At least 4 weeks since prior radiotherapy~* At least 30 days since prior participation in another clinical trial~* No prior or concurrent prophylactic phenytoin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).